Twenty-one changemakers have been selected to receive a 2018 OncLive Giants of Cancer Care® award.
Twenty-one changemakers have been selected to receive a 2018 OncLive Giants of Cancer Care® award. The august group represents the largest class of inductees since the awards program was established in 2013. Recipients must be catalysts for change, demonstrating great accomplishment, imagination, inspiration, courage, and—perhaps most important—a true sense of urgency. The 2018 winners were recognized on Thursday, May 31, during an exclusive celebration at the Adler Planetarium in Chicago, Illinois.
This year, a record number of individuals were nominated to receive the Giants award. These exceptional physicians and researchers have challenged the reigning paradigms in oncology with their innovative and groundbreaking contributions to patient care, clinical practice, and translational research. This year also marks the program’s largest international contingent, with almost 2 dozen nominees from outside the United States.
A 7-member advisory board chaired by Patrick I. Borgen, MD, reviewed the career achievements of the nominees, narrowing the field to 171 trailblazers, who were then voted on by an elite selection committee of distinguished oncologists and hematologists. “There were a lot of great candidates across all the diseases,” said Borgen, who serves as chairman of the Department of Surgery and director of the Maimonides Breast Program at Maimonides Medical Center in Brooklyn, New York.
The winners represent 21 categories of practice and investigation: breast cancer; cancer diagnosis; CNS malignancies; community outreach, education, and cancer policy; drug development; gastrointestinal cancer; genitourinary cancer; gynecologic cancer; head and neck cancers; immunooncology, including cell-based therapies; leukemia; lung cancer; lymphoma; melanoma and skin cancers; multiple myeloma; pediatric oncology; prevention and genetics; radiation oncology; supportive care, palliative, and geriatric; surgical oncology; and translational scientific advancements. “We proudly honor and recognize the members of this incredible group of Giants of Cancer Care®,” Borgen said. “Their sacrifices, struggles, victories, and defeats must never be forgotten by future generations of men, women, and children, who may never have to watch a loved one suffer or die from cancer because of this group’s achievements.”
George W. Sledge Jr, MD, specializes in breast cancer treatment and has worked extensively to employ bioinformatics to improve the understanding and prediction of disease.
Professor, Medicine and Oncology, and Chief of the Division of Oncology, Stanford University Medical Center
Laura J. Esserman, MD, MBA, is a professor of surgery and radiology at UCSF, where she is also director of the multidisciplinary Breast Care Center.
Professor, Surgery and Radiology, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
W. K. Alfred Yung, MD, an expert in neuro-oncology, has helped develop new therapeutic strategies targeting the EGFR and PTEN/PI3K pathways and the mechanisms that promote glioma progression.
Professor, Neuro-Oncology, and the Margaret and Ben Love Chair of Clinical Care, The University of Texas MD Anderson Cancer Center
Richard L. Schilsky, MD, a specialist in new drug development and treatment of gastrointestinal cancers, has extensive experience and accomplishments in clinical medicine and research.
Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
Joseph R. Bertino, MD, focuses on mechanisms of action and resistance mechanisms of anticancer drugs, and new drug development.
Senior Adviser to the Director, Rutgers Cancer Institute of New Jersey
Josep Tabernero, MD, PhD, is involved in translational research and the effects of molecularly targeted therapies on the body.
Director, Vall d'Hebron Institute of Oncology
Nicholas J. Vogelzang, MD, is a medical oncologist who has been heavily involved in advancing genitourinary (GU) oncology through clinical trials in the cooperative group setting.
Medical Director, US Oncology Research/Comprehensive Cancer Centers of Nevada (CCCN)
Maurie Markman, MD, has conducted practice-changing research into ovarian cancer and is bringing precision medicine to the forefront of patient care throughout a national hospital network.
President, Medicine & Science, Cancer Treatment Centers of America (CTCA)
Waun Ki Hong, MD, DMSc (Hon) developed larynx-sparing, less invasive treatments for head and neck cancer. He has also championed the development of chemoprevention and personalized therapy.
Semi-Retired Head, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Lieping Chen, MD, PhD, has been integral to the discovery of the PD-1/PD-L1 pathway and its immune-suppressive functions.
Co-Director, Cancer Immunology Program, Yale Cancer Center
Michael J. Keating, MB, BS, has devoted much of his career to finding the means of controlling and curing chronic lymphocytic leukemia (CLL).
Professor, Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Bruce E. Johnson, MD, is a noted lung cancer physician-—scientist who serves as chief clinical research officer at Dana-Farber Cancer Institute.
Chief Clinical Research Officer and Professor, Medicine, Dana-Farber Cancer Institute/Harvard Medical School
James O. Armitage, MD, is a leading expert in the treatment of non-Hodgkin lymphoma, Hodgkin disease, and CLL and has played a critical role in advancing bone marrow transplantation.
Joe Shapiro Professor, Medicine, Division of Oncology and Hematology, University of Nebraska Medical Center (UNMC)
Caroline Robert, MD, PhD, has solidly established the role of immune therapies in advanced melanoma thanks to her groundbreaking work on the clinical trials evaluating anti—CTLA-4 as well as anti–PD-1 antibodies.
Head, Dermatology Unit, Institut Gustave Roussy
Bart Barlogie, MD, has been at the forefront of many research efforts in the advancement of knowledge about multiple myeloma.
Professor, Medicine, Department of Hematology and Oncology, The Icahn School of Medicine at Mount Sinai
Michael P. Link, MD, has pioneered new strategies for the management of common childhood cancers.
Lydia J. Lee Professor, Pediatric Cancer, Department of Pediatrics, Stanford University School of Medicine
Judy E. Garber, MD, MPH, is a dedicated researcher who has worked to identify individuals with genetic factors that place them at high risk of cancer. Her goal is to develop strategies to reduce that risk.
Director, Center for Cancer Genetics and Prevention, Dana-Farber Cancer Institute
Eli J. Glatstein, MD, has developed many advancements in the use of radiation oncology to reduce surgery and improve outcomes in medical oncology.
Morton M. Kligerman Professor, Radiation Oncology, Perelman School of Medicine
Armando Giuliano, MD, is a clinician—researcher focused on the treatment of early breast cancer and improvements in the quality of life of patients with breast cancer.
Linda and Jim Lippman Chair, Surgical Oncology, and Co-Director, Saul and Joyce Brandyman Breast Center, Cedars-Sinai Medical Center
Patricia A. Ganz, MD, specializes in cancer survivorship and the late effects of cancer treatment.
Professor, Medicine, David Geffen School of Medicine at the University of California, Los Angeles (UCLA) Director, Center for Cancer Prevention & Control Research, UCLA Jonsson Comprehensive Cancer Center
V. Craig Jordan, OBE, PhD, DSc, is recognized for the discovery of the breast cancer prevention properties of tamoxifen, the original selective estrogen receptor modulator (SERM).
Professor, Breast Medical Oncology, and Professor, Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center
The Giants of Cancer Care® program honors individuals who have contributed to the advancement in the understanding of cancer and the treatment of patients. Recipients must embody a set of sterling qualities: selflessness, compassion for patients, and a desire to understand and develop life-changing anticancer treatments.